Wolfgang Fureder

Vienna, Austria

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 18 publications

Successful switch from pegcetacoplan to iptacopan after repeated severe breakthrough hemolysis events - case report.

Successful switch from pegcetacoplan to iptacopan after repeated severe breakthrough hemolysis events - case report.

Journal: Hematology (Amsterdam, Netherlands)
Published: September 20, 2025

Ravulizumab exposure in early pregnancy.

Ravulizumab exposure in early pregnancy.

Journal: Annals of hematology
Published: January 14, 2025

Persistent parvovirus B19 infection in a heavily pretreated lymphoma patient receiving mosunetuzumab.

Persistent parvovirus B19 infection in a heavily pretreated lymphoma patient receiving mosunetuzumab.

Journal: Leukemia & lymphoma
Published: September 24, 2024

Ravulizumab demonstrates long-term efficacy, safety and favorable patient survival in patients with paroxysmal nocturnal hemoglobinuria.

Ravulizumab demonstrates long-term efficacy, safety and favorable patient survival in patients with paroxysmal nocturnal hemoglobinuria.

Journal: Annals of hematology
Published: July 16, 2024

Management of paroxysmal nocturnal hemoglobinuria with low-level hemolysis in pregnancy- a report of two cases.

Management of paroxysmal nocturnal hemoglobinuria with low-level hemolysis in pregnancy- a report of two cases.

Journal: Annals of hematology
Published: June 27, 2024

Resolution of extravascular hemolysis with oral iptacopan monotherapy in a patient with treatment experienced paroxysmal nocturnal hemoglobinuria (PNH).

Resolution of extravascular hemolysis with oral iptacopan monotherapy in a patient with treatment experienced paroxysmal nocturnal hemoglobinuria (PNH).

Journal: Wiener klinische Wochenschrift
Published: April 27, 2024

Stable responses to danicopan as add-on to ravulizumab in two patients with paroxysmal nocturnal hemoglobinuria.

Stable responses to danicopan as add-on to ravulizumab in two patients with paroxysmal nocturnal hemoglobinuria.

Journal: Annals of hematology
Published: April 06, 2024

Phase 3 Study of Subcutaneous Versus Intravenous Ravulizumab in Eculizumab-Experienced Adult Patients with PNH: Primary Analysis and 1-Year Follow-Up.

Phase 3 Study of Subcutaneous Versus Intravenous Ravulizumab in Eculizumab-Experienced Adult Patients with PNH: Primary Analysis and 1-Year Follow-Up.

Journal: Advances in therapy
Published: August 08, 2022

Switching From High-Dose Eculizumab to Ravulizumab in Paroxysmal Nocturnal Hemoglobinuria: A Case Report.

Switching From High-Dose Eculizumab to Ravulizumab in Paroxysmal Nocturnal Hemoglobinuria: A Case Report.

Journal: HemaSphere
Published: May 13, 2020

Prognostic factors and follow-up parameters in patients with paroxysmal nocturnal hemoglobinuria (PNH): experience of the Austrian PNH network.

Prognostic factors and follow-up parameters in patients with paroxysmal nocturnal hemoglobinuria (PNH): experience of the Austrian PNH network.

Journal: Annals of hematology
Published: November 22, 2019

Ravulizumab (ALXN1210) vs eculizumab in adult patients with PNH naive to complement inhibitors: the 301 study.

Ravulizumab (ALXN1210) vs eculizumab in adult patients with PNH naive to complement inhibitors: the 301 study.

Journal: Blood
Published: September 26, 2018

Normal and pathological erythropoiesis in adults: from gene regulation to targeted treatment concepts.

Normal and pathological erythropoiesis in adults: from gene regulation to targeted treatment concepts.

Journal: Haematologica
Published: March 06, 2018
Showing 1-12 of 18

Last Updated: 09/26/2026